Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sibrotuzumab in Metastatic Colorectal Cancer
NCT02198274Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2000
- Primary completion
- Oct 2000
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of sibrotuzumab in metastatic colorectal cancer (mCRC), sponsored by Boehringer Ingelheim. Started Feb 2000; status: completed.
02
Drugs
sibrotuzumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT02198274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02198274.